ClinicalTrials.gg
Active, not recruitingNCT03620266BioDiaMIUpdated Mar 23, 2026

Effects of Bilberry and Oat Intake After Type 2 Diabetes and/or MI

An interventional study of Bilberry and Placebo in Myocardial Infarction, sponsored by Ole Frobert, MD, PhD. Active, not recruiting at 8 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-23.

Sponsored by Ole Frobert, MD, PhD · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
900
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 90 studies in Myocardial Infarction with a site in Sweden — 13 open to participants now, 22 under way, 4 of them phase 3. Myocardial Infarction · Sweden.

Planned enrollment
34th of 70
900 · median 875
Started
2021
with 5 others
No phase
23 of 90
6 open now
Primary completion
2026-12
later than 9 of 21 live
Registered
58th of 90
by date
Lead sponsor
2 of 90
Ole Frobert, MD, PhD

Among the 90 studies in Myocardial Infarction with a site in Sweden, this one is the 34th largest by planned enrollment of the 70 interventional ones that give a count, is one of 6 that started in 2021, is one of 23 with no phase, reaches primary completion later than 9 of the 21 other live ones, and was the 58th registered.

Myocardial Infarction

2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

13 of the 90 studies in Myocardial Infarction with a site in Sweden are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies in Myocardial Infarction with a site in Sweden, or all of them as a file.
02

Study summary

Background:

Bilberries from Sweden, rich in polyphenols, have shown cholesterol-lowering effects in small studies, and the cholesterol-lowering properties of oats, with abundant beta-glucans and potentially bioactive phytochemicals, are well established. Both may provide cardiometabolic benefits for patients with manifest chronic cardiometabolic disease, such as type 2 diabets mellitus (T2DM) and myocardial infarction (MI). However, large studies of adequate statistical power and appropriate duration are needed to confirm clinically relevant treatment effects. No previous study has evaluated the potential additive or synergistic effects of bilberry combined with oats on cardiometabolic risk factors.

Design:

This is a double-blind, randomized, placebo-controlled clinical trial. Our primary objective is to assess cardioprotective effects of diet supplementation with dried bilberry and with bioprocessed oat bran, with a secondary explorative objective of assessing their combination, compared with a neutral isocaloric reference supplement, for patients diagnosed with T2DM and/or MI. Patients will be randomized 1:1:1:1 to a three-month intervention. The primary endpoint is the difference in LDL cholesterol change between the intervention groups after three months. The major secondary endpoint is exercise capacity at three months. Other secondary endpoints include plasma concentrations of biochemical markers of inflammation, glycaemia, and gut microbiota composition after three months.

Implications:

Secondary prevention after cardiometabolic disease, including T2DM and MI, has improved during the last decades but diabetes complications, readmissions and cadiovascular related deaths following these conditions remain large health care challenges. Controlling hyperlipidemia, hyperglycaemia, hypertension and inflammation is critical to preventing (new) cardiovascular events, but novel pharmacological treatments for these conditions are expensive and associated with negative side effects. If bilberry and/or oat, in addition to standard medical therapy, can lower LDL cholesterol and inflammation more than standard therapy alone, this could be a cost-effective and safe dietary strategy for secondary prevention in high-risk patients or risk prevention in subjects with T2DM.

03

Conditions studied

  • Myocardial Infarction

Keywords

  • acute myocardial infarction
  • diet therapy
  • anthocyanin
  • bilberry bush
  • exercise capacity
  • cholesterol
  • beta glucans
  • type 2 diabetes mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed T2DM diagnosis (any treatment modality accepted) and/or within 3 years post STEMI or NSTEMI
  • Completed coronary angiography/PCI
  • Male and female subjects ≥18 years
  • Allocated to atorvastatin at a daily dose of 80 mg (only eligible for patients enrolled up to 7 days post MI and not for T2D subjects)
  • Written

Exclusion criteria

Exclusion criteria

  • Emergency coronary artery bypass grafting
  • \<18 years of age
  • LDL cholesterol \<2.0 mmol/L
  • Daily intake or the intent to initiate daily intake of bilberry in any form or daily intake of >15 g of oatmeal or equivalent
  • Food allergy/intolerance to gluten, bilberries or legumes
  • Previous randomization in the BioDiaMI trial
  • Inability to provide
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
900 participants (estimated)

Study arms

  • Experimental
    Bilberry

    Dietary supplement with bilberry shakes 2 times daily for 3 months (containing in total 40g of dried bilberry powder equalling 480 g of fresh berries per day). Product development in collaboration with Glucanova AB.

    Dietary Supplement: Bilberry

  • Placebo comparator
    Reference/Placebo

    Dietary supplement with reference shakes 2 times daily for 3 months (containing no active bilberry or no active oats, but with similar texture and taste as both bilberry and oat). Product development in collaboration with Glucanova AB.

    Dietary Supplement: Placebo

  • Experimental
    Bioprocessed oat bran

    Dietary supplement with bioprocessed oat bran shakes 2 times daily for 3 months (containing beta glucans from the Glucanova® technology, invented by Glucanova AB).Product development in collaboration with Glucanova AB.

    Dietary Supplement: Bioprocessed oat bran

  • Experimental
    Combination of oat and bilberry

    Dietary supplement with a combination of bioprocessed oat bran and dried bilberry (shakes) 2 times daily for 3 months. Product development in collaboration with Glucanova AB.

    Dietary Supplement: Combination bilberry/oats

Interventions

  • Dietary supplementVaccinium myrtillus extractStudies of Vaccinium myrtillus extractVaccinium myrtillus extract pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The dietary intervention will continued for three months. After randomization, participants will be given bilberry shakes (active), liquid oat shakes (active), a combination shake with bilberry and oats, or reference shakes (placebo product containing no active bilberry or active oats but with similar taste and texture as both oat and bilberry), for intake two times a day (t.i.d). The formula for the shakes to be used in the intervention will be finalized during the initial project period.

  • Dietary supplementPlacebo

    The dietary intervention will be continued for three months. After randomization, participants will be given bilberry shakes (active), liquid oat shakes (active), a combination shake with bilberry and oats, or reference shakes (placebo product containing no active bilberry or active oats but with similar taste and texture), for intake two times a day (t.i.d). The formula for the shakes to be used in the intervention will be finalized during the initial project period.

  • Dietary supplementBioprocessed oat bran

    The dietary intervention will be continued for three months. After randomization, participants will be given bilberry shakes (active), liquid oat shakes (active), a combination shake with bilberry and oats, or reference shakes (placebo product containing no active bilberry or active oats but with similar taste and texture), for intake two times a day (t.i.d). The formula for the shakes to be used in the intervention will be finalized during the initial project period.

  • Dietary supplementCombination bilberry/oats

    The dietary intervention will be continued for three months. After randomization, participants will be given bilberry shakes (active), liquid oat shakes (active), a combination shake with bilberry and oats, or reference shakes (placebo product containing no active bilberry or active oats but with similar taste and texture), for intake two times a day (t.i.d). The formula for the shakes to be used in the intervention will be finalized during the initial project period.

06

What researchers measure

Primary outcomes

  1. Plasma levels of LDL cholesterol

    The effect of intervention on difference between the groups of LDL cholesterol after three months

    Time frame: Three months

Secondary outcomes

  1. Plasma lipid profile

    The effect of intervention on differences between the groups of fasting lipid profile including HDL, triglycerides, total cholesterol, small-dense LDL cholesterol, apo A, apo B, Lp(a) and oxidized LDL.

    Time frame: Three months

  2. Symptom-limited bicycle ergometer test

    The effect of intervention on exercise capacity (measured as maximal workload in Watts and as estimated maximal oxygen uptake (VO2 max))

    Time frame: Three months

  3. Dynamic unilateral heel-lft and unilateral shoulder flexion tests

    The effect of intervention on muscle endurance

    Time frame: Three months

  4. Self-reported physical activity level

    The effect of intervention on the Frändin/Grimby activity scale (6 levels of physical activity, min:1 (low activity) max:6 (heavy activity)) and the Haskell physical activity scale ("For how many days were you physically active during the last week for at least 20 minutes?", min:0 max:7)

    Time frame: Three months

  5. Plasma Cardiac Troponin Concentration

    Change in plasma cardiac troponin (high-sensitivity cardiac troponin T or I) concentration from baseline to 3 months to assess myocardial injury. The effect of intervention on Troponin levels, Unit of Measure: ng/L

    Time frame: Three months

  6. Plasma NT-proBNP Concentration

    Change in plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration from baseline to 3 months to assess cardiac stress, pg/mL

    Time frame: Three months

  7. Plasma hs-CRP Concentration

    Change in plasma high-sensitivity C-reactive protein (hs-CRP) concentration from baseline to 3 months to assess systemic inflammation. Unit of Measure: mg/L

    Time frame: Three months

  8. Plasma IL-6 Concentration

    Change in plasma interleukin-6 (IL-6) concentration from baseline to 3 months to assess inflammatory response. Unit of Measure: pg/mL

    Time frame: Three months

  9. Glycosylated Hemoglobin (HbA1c)

    Change in glycosylated hemoglobin (HbA1c) from baseline to 3 months to assess glycemic control. Unit of Measure: %

    Time frame: Three months

  10. Fasting Plasma Insulin Concentration

    Change in fasting plasma insulin concentration from baseline to 3 months to assess insulin sensitivity and metabolic status. Unit of Measure: µIU/mL (micro-international units per milliliter)

    Time frame: Three months

  11. Fasting Plasma C-Peptide Concentration

    Change in fasting plasma C-peptide concentration from baseline to 3 months to assess endogenous insulin secretion and beta-cell function. Unit of Measure: ng/mL

    Time frame: Three months

  12. Serum Creatinine Concentration

    Change in serum creatinine concentration from baseline to 3 months to assess renal function. Unit of Measure: mg/dL

    Time frame: Three months

  13. Fasting Plasma Glucose Concentration

    Change in fasting plasma glucose concentration from baseline to 3 months to assess glycemic control. Unit of Measure: mg/dL Unit of Measure: mg/dL

    Time frame: Three months

  14. Serum Cystatin C Concentration

    Change in serum cystatin C concentration from baseline to 3 months to assess renal function and estimate glomerular filtration independent of muscle mass. Unit of Measure: mg/L Unit of Measure: mg/dL Unit of Measure: mg/dL

    Time frame: Three months

  15. Untargeted plasma metabolome

    Untargeted plasma metabolomics will be employed to exploratively assess alterations in endogenous and exposome-related metabolites and to identify metabolites that may differ with treatment.

    Time frame: Three months

  16. Fecal samples of gut microbiota composition

    These exploratory analyses of will allow to investigate the extent to which gut microbiota composition and activity differs between responders and non-responders to the interventions.

    Time frame: Three months

  17. Left ventricular systolic function

    The effect of intervention on left ventricular function. Baseline left ventricular systolic function, expressed as global ejection fraction in percent according to the biplane Simpson method, will be evaluated by echocardiography by the discharging physician. The procedure will be repeated after three months by an experienced echocardiography technician blinded to results of the initial examinations

    Time frame: Three months

  18. Resting heart rate

    The effect of intervention on resting heart rate

    Time frame: Three months

  19. Systolic and diastolic blood pressure

    The effect of intervention on blood pressure (mmHg)

    Time frame: Three months

  20. Urine albumin-creatinine ratio

    Urine albumin-creatinine ratio will be measured for for T2DM only

    Time frame: Three months

  21. Continuous glucose monitoring with Continuous Glucose Monitors (CGM) - FreeStyle model 2

    Continuous glucose monitoring (in a subset of T2DM only, n=100 in total)

    Time frame: Three months

  22. Body composition with multi-frequency bioimpedance

    The effect of intervention on body composition measured with multi-frequency bioimpedance (for T2DM only)

    Time frame: Three months

  23. Diabetic retinal changes

    The effect of intervention on diabetic retinal changes (eye fundus examination) (in a subset of T2DM only, n=100 in total)

    Time frame: Three months

  24. Platelet aggregation (Primary hemostasis)

    Ex vivo platelet aggregation in whole blood measured with impedance aggregometry (Multiplate®, Roche, Switzerland) after stimulation with adenosine diphosphate (ADP), arachidonic acid and thrombin-related activation peptide (TRAP-6). Unit of measure: Aggregation units x min. (in a subset of T2DM only, n=100 in total)

    Time frame: Three months

  25. P-selectin levels (Primary hemostasis)

    Plasma concentration of P-selectin measured with commercial ELISA (CD62P Quantikine, Biotechne, Dublin, Ireland). Unit of measure: ng/mL. (in a subset of T2DM only, n=100 in total)

    Time frame: Three months

  26. Ex vivo thrombin generation (Secondary hemostasis)

    Ex vivo thrombin generation (endogenous thrombin potential) in platelet-poor plasma measured using Calibrated Automated Thrombogram (BV Thrombinoscope, Maastricht, the Netherlands) after stimulation with tissue factor. Unit of measure: nM x min. (in a subset of T2DM only, n=100 in total)

    Time frame: Three months

  27. Prothrombin fragment 1+2 (Secondary hemostasis)

    Plasma concentration of prothrombin fragment 1+2, measured with commercial ELISA (EnzygnostTM, Siemens Healthineers, Ballerup, Denmark). Unit of measure: pmol/L. (in a subset of T2DM only, n=100 in total)

    Time frame: Three months

  28. Fibrinolysis speed

    Ex vivo fibrinolytic capacity (fibrinolysis speed) in whole blood measured with in-house modified rotational thromboelastometry after stimulation with tissue factor and tissue plasminogen activator. Unit of measure: mm/min. (in a subset of T2DM only, n=100 in total)

    Time frame: Three months

  29. Fibrinolytic capacity

    Ex vivo fibrinolytic capacity (time from peak fibrin to 50% lysis) in platelet-poor plasma measured with in-house turbidimetric fibrin formation and lysis assay. Unit of measure: seconds. (in a subset of T2DM only, n=100 in total)

    Time frame: Three months

  30. Fibrinolytic markers

    Plasma concentrations of plasminogen activity, tissue plasminogen activator (unit of measure: ng/mL) and plasminogen activator inhibitor-1 (unit of measure: ng/mL) measured with ELISA (Technozym®, Technoclone, Vienna, Austria). (in a subset of T2DM only, n=100 in total)

    Time frame: Three months

  31. Endothelial activation

    Plasma concentrations of syndecan-1 (unit of measure: ng/mL) and thrombomodulin (unit of measure: ng/mL) measured with commercial ELISA kits (CD138 kit and CD141 kit, Diaclone, Medix Biochemica, Espoo, Finland). (in a subset of T2DM only, n=100 in total)

    Time frame: Three months

  32. Inflammation

    The effect of intervention on inflammatory markers (Olink panel) (in a subset of T2DM only, n=100 in total)

    Time frame: Three months

  33. Oxidative stress

    The effect of intervention on 8-Oxo-2'-deoxyguanosine levels (in a subset of T2DM only, n=100 in total)

    Time frame: Three months

07

Study locations

8 sites
08

References and documents

Publications

  • Bergh C, Landberg R, Andersson K, Heyman-Linden L, Rascon A, Magnuson A, Khalili P, Karegren A, Nilsson J, Pirazzi C, Erlinge D, Frobert O. Effects of Bilberry and Oat intake on lipids, inflammation and exercise capacity after Acute Myocardial Infarction (BIOAMI): study protocol for a randomized, double-blind, placebo-controlled trial. Trials. 2021 May 10;22(1):338. doi: 10.1186/s13063-021-05287-5. PubMed 33971938 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2021 (actual). Primary completion is estimated for Dec 2026, 63 months after the start.

Of 322 non-industry interventional studies with no phase under Myocardial Infarction, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 58. This study's planned 63 months is above that.

Counting every sponsor, half of 355 studies reached it within 34 months; a quarter within 15 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2018
First posted
Aug 8, 2018
StartActual
Sep 30, 2021
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Mar 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03620266
Lead sponsor
Ole Frobert, MD, PhD
Collaborators
Region Västmanland, Region Skane, Chalmers University of Technology, Värmland County Council, Sweden, Vastra Gotaland Region, Aarhus University Hospital, Odense University Hospital, Falu Hospital
Responsible party
Ole Frobert, MD, PhD (Professor, Region Örebro County) — Sponsor-investigator
First posted
Aug 8, 2018
Start date
Sep 30, 2021
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Mar 23, 2026

Study contacts

Ole Frobert, Prof
study director · Department of Cardiology, Örebro Univerity Hospital, 701 85 Örebro, Sweden
Cecilia Bergh, PhD
principal investigator · Clinical Epidemiology and Biostatistics, School of medical Sciences, örebro University, Sweden

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vaccinium myrtillus extract

Start the discussion